Alterity Therapeutics Statistics
Total Valuation
PRNAF has a market cap or net worth of 58.37 million. The enterprise value is 55.53 million.
| Market Cap | 58.37M |
| Enterprise Value | 55.53M |
Important Dates
The last earnings date was Thursday, April 24, 2025.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 9.13B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +104.33% |
| Shares Change (QoQ) | +10.82% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 7.39B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.32 |
| PB Ratio | 12.11 |
| P/TBV Ratio | 12.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.53 |
| EV / Sales | 23.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.84, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.84 |
| Quick Ratio | 3.76 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -155.77% and return on invested capital (ROIC) is -99.57%.
| Return on Equity (ROE) | -155.77% |
| Return on Assets (ROA) | -78.37% |
| Return on Invested Capital (ROIC) | -99.57% |
| Return on Capital Employed (ROCE) | -262.19% |
| Revenue Per Employee | 230,490 |
| Profits Per Employee | -1.22M |
| Employee Count | 10 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6,850.00% in the last 52 weeks. The beta is 0.58, so PRNAF's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +6,850.00% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 55.95 |
| Average Volume (20 Days) | 8,274 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PRNAF had revenue of 2.30 million and -12.25 million in losses. Loss per share was -0.00.
| Revenue | 2.30M |
| Gross Profit | 2.19M |
| Operating Income | -12.70M |
| Pretax Income | -12.22M |
| Net Income | -12.25M |
| EBITDA | -12.68M |
| EBIT | -12.70M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 2.81 million in cash and 65,494 in debt, giving a net cash position of 2.74 million.
| Cash & Cash Equivalents | 2.81M |
| Total Debt | 65,494 |
| Net Cash | 2.74M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.82M |
| Book Value Per Share | 0.00 |
| Working Capital | 4.77M |
Cash Flow
| Operating Cash Flow | -10.19M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 95.14% |
| Operating Margin | -551.15% |
| Pretax Margin | -530.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PRNAF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -104.33% |
| Shareholder Yield | -104.33% |
| Earnings Yield | -20.98% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PRNAF has an Altman Z-Score of -29.73. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -29.73 |
| Piotroski F-Score | n/a |